Corporate Snapshot

Gentium S.p.A. ("Gentium" or "the Company") is a biopharmaceutical company engaged in researching, discovering, developing, and manufacturing drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Gentium's most advanced candidate, Defibrotide, is in development to treat and prevent severe hepatic veno-occlusive disease (VOD) with multiple organ failure (MOF), a condition in which some of the veins in the liver are blocked as a result of toxic cancer treatments, such as chemotherapy. Defibrotide may protect the vascular endothelial cells, particularly those of small vessels, from damage and activation. Gentium's research and development program includes several ongoing clinical studies. Gentium also has several product candidates in preclinical development for use subsequent to stem cell transplantation (SCT), to prevent deep vein thrombosis (DVT), for inflammatory bowel disease (IBD), and oral mucositis. Oral Defibrotide is in development to treat multiple myeloma, a cancer of the plasma cell. In 1986, one of Gentium's predecessor companies received approval to sell Defibrotide in Italy to treat DVT; later the indication was revised to treat and prevent all vascular disease with risk of thrombosis (also in Italy). The Company currently derives revenues from the manufacture and sale of active pharmaceutical ingredients, reporting EUR 3.3 million (US$4 million) in total revenues for 2005. Gentium independently operates as a research facility as well as a production plant for these marketed substance pharmaceuticals in Villa Guardia, near Como, Italy. Effective May 16, 2006, Gentium's American Depository Shares (ADSs) were listed for trading on the NASDAQ National Market System (NMS-NASDAQ) under the symbol GENT, from its prior AMEX listing under the symbol GNT.

* The Corporate Snapshot was last updated on June 26, 2006.

Latest Research

Executive
InformationalOverview

2006-06-26

Click to View

Stock Information (GENT-NASDAQ)